Perrigo gets tentative approval for second strength of Picato Gel generic

Press enter to search
Close search
Open Menu

Perrigo gets tentative approval for second strength of Picato Gel generic

By David Salazar - 11/07/2017

DUBLIN — Little more than a week after its first tentative approval for its 0.015% formulation of its Picato Gel generic, Perrigo has gained tentative approval from the Food and Drug Administration for a higher strength generic. The company’s ingenol mebutate, 0.05%, is indicated to treat actinic keratosis.


“This tentative approval, along with the tentative approval previously received for ingenol mebutate gel 0.015%, illustrates the continued dedication of our [research and development] and regulatory teams as they work to advance our new product pipeline.” Perrigo president Rx pharmaceuticals John Wesolowski said.


The drug had U.S. sales of approximately $16 million, Perrigo said. The company said that its submission date made it the first to file for a generic of this product.


RELATED TOPICS